In early-phase clinical trials, the efficacy of NKG2D-CAR T cells has been demonstrated in patients with acute myeloid leukemia, myelodysplastic syndrome, and relapsing/refractory MM. Here, KLRK1 is linked to Miyoshi myopathy.